Table 2.
Summary of Primary and Secondary Outcomes According to Medication in All Patients
| Outcomes | Propofol (n = 962) | Ketamine (n = 792) | Etomidate (n = 919) | p |
|---|---|---|---|---|
| Ventilator duration (hr), median (quartile 1, quartile 3) | 35.9 (12.7–95.1) | 35.6 (11.9–85.8) | 40.3 (15.5–90.3)b,c | < 0.001 |
| Hospital length of stay (d), median (quartile 1, quartile 3) | 13.9 (7.3–25.5) | 13.9 (6.7–27.8)a | 11.9 (6.2–21.5) | 0.003 |
| Hospital mortality, n (%) | 219 (23) | 251 (32)a | 297 (32)b | < 0.001 |
| ICU length of stay (d), median (quartile 1, quartile 3) | 4.5 (2.0–9.1) | 4.2 (2.0–9.3)a | 4.7 (2.2–9.0)b | < 0.001 |
| ICU mortality, n (%) | 125 (13) | 177 (22)a | 208 (23)b | < 0.001 |
Pairwise p values are from Pearson χ2 tests for categorical variables and Kruskal-Wallis rank-sum tests for continuous variables with statistical significance defined by p < 0.017 after Bonferroni correction (aketamine vs propofol, betomidate vs propofol, cetomidate vs ketamine). The comparisons do not account for multiple observations per subject. p values for ventilator duration, hospital, and ICU length of stay are from the analysis of ventilator-, hospital-, and ICU-free days (of 7, 28, and 28 d, respectively).